Emalex Biosciences is a biopharmaceutical company dedicated to developing new treatments for rare and orphan neurological conditions. Their first development candidate, Ecopipam, is a novel compound studied as a potential treatment for central nervous system (CNS) disorders, including pediatric Tourette Syndrome.

Emalex Biosciences, LLC

Emalex Biosciences, LLC is a biopharmaceutical company dedicated to the development of new treatments for rare and orphan neurological conditions. Ecopipam, its first development candidate, is a novel compound that has been studied as a potential treatment for many central nervous system (CNS) disorders, including pediatric Tourette Syndrome. The latter is a childhood-onset neurodevelopmental condition characterized by motor and vocal tics for which very few safe and effective therapies exist.

Horizon Technology Finance

Valor Equity Partners

Paragon Biosciences

Fidelity Management and Research Company

Bain Capital Life Sciences

Emalex Biosciences

We are conducting a Phase 3 clinical trial for a potential therapeutic to treat Tourette syndrome. The study evaluates a therapeutic in children, adolescents and adults. Sites are in North America and Europe. Study details are available here: https://lnkd.in/gm_Sxfvy

#tourettesyndrome #clinicaltrial 

Remembering Dr. Martin Luther King, Jr. today. His commitment to combating injustice and fostering inclusivity continues to inspire. #martinlutherkingjr 

msh id	COM:EMALEXBIOSCIENCES
symbol	-
name	Emalex Biosciences, LLC
homepage url	https://emalexbiosciences.com
country	US
sector	Healthcare & Health Services
industry	Biopharmaceutical
market	PRIVATE
employee count	18
crunchbase url	https://www.crunchbase.com/organization/emalex-biosciences-inc
linkedin url	https://www.linkedin.com/company/emalex-biosciences
founders	-

market cap	-
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	-
growth score 28	-
growth score 90	-
growth score 365	-

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	-
growth cost of revenue	-
growth depreciation and amortization	-
growth ebitda	-
growth ebitda ratio	-
growth eps	-
growth eps diluted	-
growth general and administrative expenses	-
growth gross profit	-
growth gross profit ratio	-

COM:EMALEXBIOSCIENCES

Emalex Biosciences, LLC

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	-
cost of revenue	-
depreciation and amortization	-
ebitda	-
ebitda ratio	-
eps	-
eps diluted	-
operating expenses	-
operating income	-
operating income ratio	-

accounts receivables	-
capital expenditure	-
cash at beginning of period	-
cash at end of period	-
inventory	-
working capital ttm	-

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-